

[54] **CONTINUOUS RELEASE FORMULATIONS**[75] **Inventors:** **Jeffrey R. Churchill**, Northwich;  
**Francis G. Hutchinson**, Lymm, both  
of United Kingdom[73] **Assignee:** **Imperial Chemical Industries**,  
London, England[21] **Appl. No.:** **716,651**[22] **Filed:** **Mar. 27, 1985****Related U.S. Application Data**[62] Division of Ser. No. 485,454, Apr. 15, 1983, Pat. No.  
4,526,938.[30] **Foreign Application Priority Data**

Apr. 22, 1982 [GB] United Kingdom ..... 8211704

[51] **Int. Cl.<sup>5</sup>** ..... **A61K 31/74; A61K 31/79;**  
A61F 2/00[52] **U.S. Cl.** ..... **424/423; 424/78;**  
424/80; 424/422; 424/499[58] **Field of Search** ..... 424/19, 28, 78, 81[56] **References Cited****PUBLICATIONS**Das, "Controlled Release Technology" John Wiley and  
Sons, Inc. 1983 pp. 9-10.*Primary Examiner*—Frederick E. Waddell  
*Attorney, Agent, or Firm*—Cushman, Darby & Cushman[57] **ABSTRACT**

Pharmaceutical compositions comprising a pharmacologically active polypeptide and a pharmacologically or veterinarily acceptable amphipathic, non-cross-linked linear, branched or graft block copolymer, which has a minimum weight average molecular weight of 5,000, in which the hydrophobic component is biodegradable and the hydrophilic component may or may not be biodegradable, the composition being capable of absorbing water to form a hydrogel when placed in an aqueous, physiological-type environment; copolymers suitable for use in said compositions; and method for the manufacture of such copolymers.

**6 Claims, No Drawings**